Table 3.
Cost-effectiveness analysis results
CAD or PAD | PAD only | CAD only | |||||||
---|---|---|---|---|---|---|---|---|---|
RIV + ASA | ASA | Δ | RIV + ASA | ASA | Δ | RIV + ASA | ASA | Δ | |
Cost category (€) | |||||||||
Drug costs | 9.391 | 200 | 9.191 | 9.047 | 188 | 8.859 | 9.379 | 200 | 9.180 |
Direct health costs | 9.252 | 12.659 | − 3.407 | 14.418 | 18.962 | − 4.544 | 8.538 | 11.395 | − 2.857 |
Total cost | 18.643 | 12.858 | 5.785 | 23.465 | 19.150 | 4.315 | 17.917 | 11.594 | 6.323 |
Outcome | |||||||||
QALYs, per patient | 9.62 | 9.27 | 0.35 | 8.67 | 8.14 | 0.54 | 9.70 | 9.36 | 0.34 |
RIV + ASA vs. ASA | RIV + ASA vs. ASA | RIV + ASA vs. ASA | |||||||
ICER | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) |
Cost per QALY | 5.785 | 0.35 | 16.522 | 4.315 | 0.54 | 8.003 | 6.323 | 0.34 | 18.599 |
CAD and PAD | CAD with CKD | CAD with HF | |||||||
RIV + ASA | ASA | Δ | RIV + ASA | ASA | Δ | RIV + ASA | ASA | Δ | |
Cost category (€) | |||||||||
Drug costs | 8.877 | 183 | 8.694 | 7.913 | 165 | 7.748 | 8.734 | 179 | 8.555 |
Direct health costs | 13.408 | 16.408 | − 3.000 | 10.060 | 12.294 | − 2.234 | 7.634 | 10.049 | − 2.415 |
Total cost | 22.285 | 16.591 | 5.694 | 17.972 | 12.459 | 5.513 | 16.367 | 10.228 | 6.139 |
Outcome | |||||||||
QALYs, per patient | 8.63 | 8.07 | 0.56 | 7.76 | 7.34 | 0.43 | 8.70 | 8.08 | 0.62 |
RIV + ASA vs. ASA | RIV + ASA vs. ASA | RIV + ASA vs. ASA | |||||||
ICER | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) | Incremental costs (€) | Incremental effectiveness | Incremental ratio (€) |
Cost per QALY | 5.694 | 0.56 | 10.199 | 5.513 | 0.43 | 12.971 | 6.139 | 0.62 | 9.905 |
All costs are reported in Euros (€)
Delta symbol defines the difference between information (costs, QALYs and ICERs) for RIV+ASA vs. ASA alone
CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, RIV rivaroxaban, ASA aspirin, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio